Literature DB >> 11358834

Defects of DNA mismatch repair in human prostate cancer.

Y Chen1, J Wang, M M Fraig, J Metcalf, W R Turner, N K Bissada, D K Watson, C W Schweinfest.   

Abstract

Loss of mismatch repair (MMR) function leads to the accumulation of errors that normally occur during DNA replication, resulting in genetic instability. Germ-line mutations of MMR genes in the patients with hereditary nonpolyposis colorectal cancer lead to inactivation of MMR protein functions, and the defects of MMR are well correlated to the high rate of microsatellite instability in their tumors. Previous studies (T. Uchida, et al. Oncogene, 10: 1019-1022, 1995; S. Egawa, et al. Cancer RES:, 55: 2418-2421, 1995; J. M. Cunningham, et al. Cancer RES:, 56: 4475-4482, 1996; X. Gao, et al. Oncogene, 9: 2999-3003, 1994; H. Rohrbach, et al. Prostate, 40: 20-27, 1999) have shown that genetic instability (chromosomal and microsatellite instability) is detectable in human prostate cancer. To elucidate the role of MMR genes in the tumorigenesis of prostate cancer, we evaluated the expression of these genes in human cancer cell lines and in tumor specimens. Using Western blot analysis, we detected loss among MSH2, MLH1, PMS2, and PMS1 proteins in DU145, LNCaP, p69SV40T, M2182, and M12 cells. In addition, genomic instability in the prostate cell lines including DU145, PC3, LNCaP, p67SV40T, M2182, and M12 was detected by a microsatellite mutation assay. Significantly, immunohistochemical analysis of prostatic tissue revealed the reduction or absence of MMR protein expression in the epithelium of prostate tumor foci compared with normal adjacent prostate tissue. In contrast to hereditary nonpolyposis colorectal cancer, characterized by defects predominantly in MLH1 and MSH2, the samples we examined showed more tumor foci with loss of PMS1 and PMS2. PMS1, which is only expressed in the basal cells in normal glands, is conspicuously absent in most prostate cancer. From these results, we conclude that there are defects of MMR genes in human prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358834

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  Clinical implications of mismatch repair deficiency in prostate cancer.

Authors:  Ramy Sedhom; Emmanuel S Antonarakis
Journal:  Future Oncol       Date:  2019-06-25       Impact factor: 3.404

2.  Hereditary prostate cancer as a feature of Lynch syndrome.

Authors:  Christina M Bauer; Anna M Ray; Bronwen A Halstead-Nussloch; Robert G Dekker; Victoria M Raymond; Stephen B Gruber; Kathleen A Cooney
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

Review 3.  Single nucleotide polymorphisms in DNA repair genes and prostate cancer risk.

Authors:  Jong Y Park; Yifan Huang; Thomas A Sellers
Journal:  Methods Mol Biol       Date:  2009

4.  Association between the hMSH2 IVS12-6 T>C polymorphism and cancer risk: A meta-analysis.

Authors:  Song Wu; Jingyu Chen; Yong Ji; Yuxin Liu; Lu Gao; Guoqiang Chen; Kai Shen; Bin Huang
Journal:  Exp Ther Med       Date:  2011-08-16       Impact factor: 2.447

Review 5.  Immunotherapy of Prostate Cancer: Facts and Hopes.

Authors:  Marijo Bilusic; Ravi A Madan; James L Gulley
Journal:  Clin Cancer Res       Date:  2017-06-29       Impact factor: 12.531

6.  The spectrum of urological malignancy in Lynch syndrome.

Authors:  P J Barrow; S Ingham; C O'Hara; K Green; I McIntyre; F Lalloo; J Hill; D G Evans
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

7.  Elevated risk of prostate cancer among men with Lynch syndrome.

Authors:  Victoria M Raymond; Bhramar Mukherjee; Fei Wang; Shu-Chen Huang; Elena M Stoffel; Fay Kastrinos; Sapna Syngal; Kathleen A Cooney; Stephen B Gruber
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

8.  Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes.

Authors:  Wendy J Langeberg; Erika M Kwon; Joseph S Koopmeiners; Elaine A Ostrander; Janet L Stanford
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

Review 9.  The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer.

Authors:  Huy Q Ta; Daniel Gioeli
Journal:  Endocr Relat Cancer       Date:  2014-08-05       Impact factor: 5.678

10.  Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin.

Authors:  Lawton J Stubbert; Jennifer M Smith; Bruce C McKay
Journal:  BMC Cancer       Date:  2010-05-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.